Citadel Advisors’s Sabra Healthcare REIT SBRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $381K | Buy |
19,800
+1,100
| +6% | +$21.7K | ﹤0.01% | 9918 |
|
|
2025
Q4 | $354K | Buy |
18,700
+6,400
| +52% | +$119K | ﹤0.01% | 9785 |
|
|
2025
Q3 | $229K | Sell |
12,300
-4,000
| -25% | -$74.7K | ﹤0.01% | 10952 |
|
|
2025
Q2 | $301K | Sell |
16,300
-60,700
| -79% | -$1.08M | ﹤0.01% | 9822 |
|
|
2025
Q1 | $1.35M | Buy |
77,000
+57,100
| +287% | +$963K | ﹤0.01% | 6300 |
|
|
2024
Q4 | $345K | Sell |
19,900
-8,400
| -30% | -$153K | ﹤0.01% | 9370 |
|
|
2024
Q3 | $527K | Sell |
28,300
-11,900
| -30% | -$201K | ﹤0.01% | 8155 |
|
|
2024
Q2 | $619K | Buy |
40,200
+20,700
| +106% | +$296K | ﹤0.01% | 7610 |
|
|
2024
Q1 | $288K | Buy |
19,500
+7,500
| +63% | +$104K | ﹤0.01% | 9534 |
|
|
2023
Q4 | $171K | Sell |
12,000
-2,100
| -15% | -$29.8K | ﹤0.01% | 10187 |
|
|
2023
Q3 | $197K | Buy |
14,100
+5,300
| +60% | +$67.8K | ﹤0.01% | 9947 |
|
|
2023
Q2 | $104K | Sell |
8,800
-2,200
| -20% | -$25K | ﹤0.01% | 10879 |
|
|
2023
Q1 | $127K | Sell |
11,000
-16,800
| -60% | -$208K | ﹤0.01% | 10909 |
|
|
2022
Q4 | $346K | Buy |
+27,800
| New | +$354K | ﹤0.01% | 9004 |
|
|
2022
Q3 | – | Sell |
-17,900
| Closed | -$250K | – | 13489 |
|
|
2022
Q2 | $250K | Buy |
17,900
+1,600
| +10% | +$21.4K | ﹤0.01% | 10223 |
|
|
2022
Q1 | $243K | Sell |
16,300
-44,900
| -73% | -$614K | ﹤0.01% | 11074 |
|
|
2021
Q4 | $829K | Sell |
61,200
-30,700
| -33% | -$434K | ﹤0.01% | 8401 |
|
|
2021
Q3 | $1.35M | Buy |
91,900
+7,200
| +9% | +$122K | ﹤0.01% | 7365 |
|
|
2021
Q2 | $1.54M | Buy |
84,700
+32,400
| +62% | +$577K | ﹤0.01% | 7255 |
|
|
2021
Q1 | $908K | Buy |
52,300
+26,100
| +100% | +$459K | ﹤0.01% | 8362 |
|
|
2020
Q4 | $455K | Sell |
26,200
-17,200
| -40% | -$274K | ﹤0.01% | 8321 |
|
|
2020
Q3 | $598K | Sell |
43,400
-31,400
| -42% | -$461K | ﹤0.01% | 6962 |
|
|
2020
Q2 | $1.08M | Buy |
74,800
+50,000
| +202% | +$657K | ﹤0.01% | 5701 |
|
|
2020
Q1 | $271K | Buy |
24,800
+11,400
| +85% | +$210K | ﹤0.01% | 7509 |
|
|
2019
Q4 | $286K | Sell |
13,400
-10,100
| -43% | -$226K | ﹤0.01% | 7658 |
|
|
2019
Q3 | $540K | Sell |
23,500
-4,100
| -15% | -$87.5K | ﹤0.01% | 6602 |
|
|
2019
Q2 | $543K | Buy |
27,600
+14,800
| +116% | +$288K | ﹤0.01% | 6700 |
|
|
2019
Q1 | $249K | Sell |
12,800
-10,500
| -45% | -$199K | ﹤0.01% | 7886 |
|
|
2018
Q4 | $384K | Buy |
23,300
+4,800
| +26% | +$96.6K | ﹤0.01% | 6852 |
|
|
2018
Q3 | $428K | Sell |
18,500
-8,100
| -30% | -$184K | ﹤0.01% | 6947 |
|
|
2018
Q2 | $578K | Sell |
26,600
-12,100
| -31% | -$236K | ﹤0.01% | 6135 |
|
|
2018
Q1 | $683K | Buy |
38,700
+14,600
| +61% | +$257K | ﹤0.01% | 5366 |
|
|
2017
Q4 | $452K | Buy |
24,100
+11,200
| +87% | +$223K | ﹤0.01% | 5798 |
|
|
2017
Q3 | $283K | Buy |
+12,900
| New | +$291K | ﹤0.01% | 6169 |
|
Other funds holding SBRA
VPM
VCM
N
Citadel Advisors's SBRA Position: Q1 2026 in Review
Citadel Advisors increased its Sabra Healthcare REIT (SBRA) stake by 382% in Q1 2026, buying an estimated $9.79M and bringing the position to 627,374 shares worth $12.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2995.
Citadel Advisors first reported a position in SBRA in Q4 2013 and has held it in 45 quarters since. The position peaked at $71.8M in Q4 2017. 459 funds tracked by Wall St. Rank hold SBRA as of Q1 2026.
- Citadel Advisors held 627,374 shares of Sabra Healthcare REIT worth $12.1M as of Q1 2026.
- Citadel Advisors bought 497,259 Sabra Healthcare REIT shares in Q1 2026, an estimated $9.79M.
- Sabra Healthcare REIT made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2995 holding.
- Citadel Advisors first reported a position in Sabra Healthcare REIT in Q4 2013 and has held it in 45 quarters since.
- Citadel Advisors's Sabra Healthcare REIT position peaked at $71.8M in Q4 2017.
- 459 funds tracked by Wall St. Rank held Sabra Healthcare REIT as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.